Pharmaceutical Industry Market Research Reports in Germany, May 2013

Germany: Country Overview, 2013, focus on Pathology

• Country report
• April 2013
• 29 pages

... And development is concentrated in two main areas: improved vaccines to protect against infectious diseases in all types of animal and the development of therapies for chronic diseases in pets. While animal ...

• Industries: Pathology
• Countries: Germany

Company Report: Prescription Drug in The United States and Germany for Year 2012

• Company report
• September 2012
• 31 pages

... To productivity for any worker performing more than simplistic sweatshop piece-work. Part 3 then shows that in major components of two key sectors of the economy, the financial and the prescription drugs sectors ...

• Industries: Prescription Drug
• Countries: United States, Germany

Company Report: Pharmaceutical in Russian Federation and Germany for Year 2012

• Company report
• October 2012
• 2 pages

• Industries: Pharmaceutical
• Countries: Russian Federation, Germany

Company Report: Drug Discovery in France and Germany for Year 2013

• Company report
• April 2013
• 2 pages

... Health will drive forward public health knowledge, which is a key issue for all governments." The french-german advanced translational drug discovery center is a unique project of public- private ...

• Industries: Drug Discovery and Development
• Countries: France, Germany

Company Report: Pathology in Germany for Year 2012

• Company report
• September 2012
• 5 pages

... Become potentially very attractive. Sirtex S largest trial assesses liver cancer suffes Response to a combination of chemotherapy and its radioactive beads, and results will be published as soon ...

• Industries: Pathology
• Countries: Germany

Company Report: Pathology in Germany and The United States for Year 2012

• Company report
• November 2012
• 4 pages

... Agennix agennix ag is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially lengthen and improve the lives of critically ...

• Industries: Pathology
• Countries: Germany, United States

Mologen AG - Company Report for Year 2012

• Company report
• August 2012
• 4 pages

... Improving the economic prospects for mologen. The initial analysis of the phase ii colorectal cancer study showed a significant prolongation of progression-free survival for the study patients treated ...

• Industries: Pathology
• Countries: Germany

Company Report: Pathology in Germany and The United States for Year 2012

• Company report
• August 2012
• 6 pages

... renal cell carcinoma. Agreement was reached with the fda to conduct a confirmatory diagnostic performance study instead of an outcomes-based study. Wilex ag is currently developing the protocol ...

• Industries: Pathology
• Countries: Germany, United States

Company Report: Pathology in The United States and Germany for Year 2012

• Company report
• August 2012
• 2 pages

... That have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need. The company's most advanced investigational agent is talactoferrin alfa ...

• Industries: Pathology
• Countries: United States, Germany

Company Report: Pathology in The United States and Germany for Year 2012

• Company report
• August 2012
• 2 pages

... That have the potential to substantially lengthen and improve the lives of critically ill patients in areas of major unmet medical need. The company's most advanced investigational agent is talactoferrin alfa ...

• Industries: Pathology
• Countries: United States, Germany

Company Report: Medicine in Germany for Year 2012

• Company report
• November 2012
• 3 pages

• Industries: Drug and Medication
• Countries: Germany

Company Report: Pharmaceutical in Germany and Jordan for Year 2012

• Company report
• August 2012
• 2 pages

• Industries: Pharmaceutical
• Countries: Germany, Jordan

Windsor AG - Company Report for Year 2012

• Company report
• October 2012
• 28 pages

• Industries: Generic Drug
• Countries: Germany

Company Report: Drug and Medication in Germany and North America for Year 2013

• Company report
• April 2013
• 2 pages

• Industries: Drug and Medication
• Countries: Germany, North America, United States

Allergy Therapeutics PLC - Annual Report 2012

• Company report
• December 2012
• 225 pages

... Therapeutics plc (aim: agy), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces the interim results for the six months ended 31 december 2012. Highlights ...

• Industries: Drug and Medication
• Countries: Germany, United States, Europe

Alimera Sciences Inc. - Investment Analysis, December 2012

• Company report
• December 2012
• 3 pages
• by Corporation

• Industries: Pharmaceutical
• Countries: Germany, Europe, United States

SBI Holdings Inc. - Company Report for Year 2012

• Company report
• November 2012
• 2 pages
• by Market Research Publisher

... A drug company engaged in 5-ala businesses under the umbrella of the group, and jointly promote the development of medicine so as to broaden the adaptation of interoperative diagnostic drugs ...

• Industries: Drug and Medication
• Countries: Germany, Japan, Europe

Company Report: Pain Therapy in Germany for Year 2012

• Company report
• December 2012
• 11 pages

... pain therapies as part of providing acute inpatient care are placed under increasing pressure in ensuring that the quality of care remains high while the costs incurred remain low. The purpose ...

• Industries: Therapy
• Countries: Germany

Global Pharmaceutical Sector Brief Analysis

• Industry report
• February 2013
• 55 pages

... Including global investigator-initiated trials (iits) in multiple indications: hcc, net, crc, melanoma establish chemosat as the standard of care (soc) for disease control in the liver 16 delcath systems ...

• Industries: Pathology
• Countries: World, Germany, Europe

The German Medicine Market : Market Statistics

• Industry report
• March 2013
• 9 pages

... Wido 2013 market penetration of drugs under patent turnover per patent drug (mill. ) Scripts per patent drug (thousands) per calendar year, starting from year of introduction into market source: avr ...

• Industries: Drug and Medication
• Countries: Germany

Pharmaceutical Sector Analysis in The United States and Germany

• Industry report
• March 2013
• 56 pages

... Drug/device combination product regulated as a drug 505(b)(2) nda by u.S. Fda Proposed indication for the treatment of patients with unresectable ocular melanoma metastatic to the liver Melblez ...

• Industries: Pathology
• Countries: World, United States, Germany

Drug and Medication in Germany and The United States : Innovation and Technology Trends

• Industry report
• August 2012
• 24 pages
• by Intergovernmental Agency

... Encephalitis tuberculosis typhoid fever varicella (chickenpox) yellow fever 16/08/2012 evolution of medical innovation from edward jenner to gavi Global vaccine market 2009 was us$24 ...

• Industries: Drug and Medication
• Countries: Germany, World, United States

Neuroleptic in Europe : Innovation and Technology Trends

• Industry report
• July 2012
• 26 pages

... Agreement that mild to severe depressions that may lead to suicide may happen during treatment with any depot neuroleptic, just as they may occur during treatment with any oral neuroleptic ...

• Industries: Drug and Medication
• Countries: Sweden, Europe, Germany

Cardiovascular Disease Sector in Germany and France

• Industry report
• September 2012
• 36 pages

... Unit dose for cerebrovascular diseases being different from that for all cardiovascular diseases there is some evidence that risk at a few hundred milligray is lower than that obtained by the lnt ...

• Industries: Pathology
• Countries: Germany, France

The European Drug and Medication Industry Brief

• Industry report
• September 2012
• 20 pages

... In cannabis / marijuana. They bind to the same cannabinoid receptors in the brain as thc. However, many of the synthetic cannabinoids are much more potent than thc. Usually the synthetic cannabinoids ...

• Industries: Drug and Medication
• Countries: Germany, Switzerland, Europe

Testosterone Sector in The United States and Germany

• Industry report
• September 2012
• 43 pages

... Are similar to those of drug addiction 09/09/2012 biochemical mechanisms anabolic steroids affect muscle mass by: 1. Increasing the production of proteins 2. Reduce recovery time by blocking the effects ...

• Industries: Drug and Medication
• Countries: United States, Germany, World

Heart Disease Industry Statistics in Spain and Germany

• Industry report
• September 2012
• 50 pages

• Industries: Pathology
• Countries: World, Spain, Germany

The German Drug Discovery and Development Industry : Innovation and Technology Trends

• Industry report
• November 2012
• 17 pages

• Industries: Drug Discovery and Development
• Countries: Germany

Pharmaceutical Key Market Figures in Germany, South Korea and The Czech Republic

• Industry report
• October 2012
• 24 pages
• by Intergovernmental Agency

... In an attempt to derive more internationally comparable results. Disease specific costing studies Mental health Combine with more detailed data cancer Rmch next steps (2) Final guidelines ...

• Industries: Pathology
• Countries: Germany, South Korea, Czech Republic

Cancer Market in The United States and Germany

• Industry report
• December 2012
• 28 pages

• Industries: Pathology
• Countries: United States, Germany